Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ALKS 2680 · RDC-264177-00

Small molecule · developed by Alkermes

Phase 2/3 Most advanced trial

ALKS Developer

2 Registered trials

What is ALKS 2680?

ALKS 2680 is an oral tablet taken once daily, available in 4 mg, 6 mg, 8 mg and 10 mg strengths. It is being studied in narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: RDC-264177-00
Drug type: Small molecule
Therapy area: Neurology
Developer: Alkermes, Inc. (ALKS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII: 3BRW4ARU66

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06767683	Phase 2/3	Narcolepsy Type 1	Recruiting	ALKS
NCT06843590	Phase 2	Idiopathic Hypersomnia	Active not recruiting	ALKS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Idiopathic HypersomniaNarcolepsy Type 1Narcolepsy Type 2

More from Alkermes

Aripiprazole Lauroxil FDA approved Samidorphan FDA approved Alixorexton Phase 3 ALKS 1140 Phase 1 ALKS 3831 Phase 3 ALKS 5461 Phase 3 ALKS 7290 Phase 2 RDN-929 Phase 1

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the ALKS page.

Follow ALKS, the company behind ALKS 2680

See ALKS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALKS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z